//fpnotebook.com/
Respiratory Syncytial Virus Vaccine
Aka: Respiratory Syncytial Virus Vaccine, RSV Vaccine, Palivizumab, Synagis
- Mechanism
- Humanized mouse Monoclonal Antibody to RSV
- Indications: Based on AAP guidelines
- Chronic lung disease in age <2 years
- Medication treatment within 6 months of RSV season start
- Hemodynamically significant Congenital Heart Disease in age <2 years
- Consider in infants with severe Immunodeficiency
- Preterm Infants during their first RSV season
- Gestational age at birth <28 weeks (Give during first RSV season)
- Gestational age at birth 28-32 weeks who are under age 6 months during RSV season
- Gestational age 32-35 weeks with 2 risk factors:
- Day care attendance
- Siblings under 5 years of age
- Congenital airway abnormality
- Congenital neuromuscular disease
- Dosing
- Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)
- Efficacy
- Decreases hospitalizations by 45 to 55%
- References
- Pickering (2009) Red Book, AAP, Elk Grove Village, p. 560